NMPA
The National Medical Products Administration of China, responsible for the approval and regulation of medical devices and pharmaceuticals.
Timeline (last 90 days)
Regulators (such as the U.S. FDA and China's NMPA) typically require prospective data, or at least rigorously designed multicenter retrospective validation, for high-risk diagnostic AI.
The EU MDR classifies diagnostic AI as a high-risk medical device requiring notified body involvement; China's NMPA manages AI-assisted diagnostic software as Class III medical devices and requires clinical trial data.
GxP is the collective term for the Good Practice series of regulations, covering GMP, GCP, GLP, and others, enforced by national drug regulatory agencies (such as the U.S. FDA and China's NMPA).
Medical-grade exoskeleton devices used for rehabilitation training or mobility assistance are classified as medical devices in most markets and require approval by drug regulatory authorities; in China they are Class II or Class III medical devices under NMPA, in the United States they follow the FDA's 510(k) or De Novo pathway, and the clinical validation cycle typically takes years.
Regulatory agencies (such as the FDA and NMPA) are increasingly inclined to require prospective evidence when approving clinical AI products.
CT scanners are high-risk medical devices subject to strict regulation by agencies such as the FDA and NMPA.
All Facts (6)
Regulators (such as the U.S. FDA and China's NMPA) typically require prospective data, or at least rigorously designed multicenter retrospective validation, for high-risk diagnostic AI.
50%UnverifiedThe EU MDR classifies diagnostic AI as a high-risk medical device requiring notified body involvement; China's NMPA manages AI-assisted diagnostic software as Class III medical devices and requires clinical trial data.
50%UnverifiedGxP is the collective term for the Good Practice series of regulations, covering GMP, GCP, GLP, and others, enforced by national drug regulatory agencies (such as the U.S. FDA and China's NMPA).
50%UnverifiedMedical-grade exoskeleton devices used for rehabilitation training or mobility assistance are classified as medical devices in most markets and require approval by drug regulatory authorities; in China they are Class II or Class III medical devices under NMPA, in the United States they follow the FDA's 510(k) or De Novo pathway, and the clinical validation cycle typically takes years.
50%UnverifiedRegulatory agencies (such as the FDA and NMPA) are increasingly inclined to require prospective evidence when approving clinical AI products.
50%UnverifiedCT scanners are high-risk medical devices subject to strict regulation by agencies such as the FDA and NMPA.
50%